17 September 2020 
EMA/CHMP/380902/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Zavicefta 
ceftazidime / avibactam 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Zavicefta. The marketing authorisation holder for this medicinal product is Pfizer Ireland Pharmaceuticals. 
The CHMP adopted an extension to the existing indication as follows:2  
Zavicefta is indicated in adults and , infants (aged 3 months and older),children aged 3 months 
and older and adolescents for the treatment of the following infections in adults (see sections 4.4 
and 5.1): 
• 
• 
Complicated intra-abdominal infection (cIAI) (in combination with metronidazole) 
Complicated urinary tract infection (cUTI), including pyelonephritis 
Zavicefta is indicated in adults for the treatment of the following infections: 
• 
Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) (see 
sections 4.4 and 5.1) 
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be 
associated with, any of the infections listed above. 
Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms 
in adults and children aged 3 months and older patients with limited treatment options (see 
sections 4.2, 4.4 and 5.1). 
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
 
 
 
 
 
the marketing authorisation has been granted by the European Commission. 
Zavicefta  
EMA/CHMP/380902/2020 
Page 2/2 
 
  
  
